Cancer: SB-715992 has entered a Phase II clinical trial for the treatment of non-small cell lung cancer and is expected to enter multiple Phase II clinical trials in other solid

EX-4.7 8 f95504a1exv4w7.txt EXHIBIT 4.7 EXHIBIT 4.7 Amendment No. 1 to Loan and Security Agreement This Amendment Agreement No. 1 ("Amendment") to the Loan and Security Agreement dated as of December 16, 1999 is entered into this 29 Th day of June, 2000 by and between Cytokinetics, Inc., a California corporation, with its chief executive offices and principal place of business at 280 East Grand Avenue, Suite 2, South San Francisco, CA 94080 ("Borrower") and Comdisco, Inc., a Delaware corporation, with its chief executive offices and principal place of business at 6111 North River Road, Rosemont, IL 60018 ("Lender"). RECITALS WHEREAS, PURSUANT to the terms and conditions set forth in the Loan and Security Agreement dated as of December 16, 1999 between Borrower and Lender (hereinafter, "Loan Agreement"), the parties have entered into that certain Secured Promissory Note dated June 29, herewith (the "Note(s)") whereby for value received, Borrower promises to pay certain payments to Lender in the original principal amount of Six Hundred Twenty Seven Thousand Five Hundred Thirteen and 27/100 Dollars ($627,513.27); WHEREAS, IN connection with the issuance of the Note, Lender and Borrower wish to amend the Loan Agreement to include the Exhibit B as required under the Loan Agreement. AGREEMENT NOW, THEREFORE, in consideration of the premises and mutual agreements contained herein, Borrower and Lender hereby agree as follows: 1. Except as expressly set forth herein, all terms used herein shall have the meanings set forth in the Loan Agreement. 2. Borrower and Lender agree that the Exhibit B attached hereto shall be incorporated and made a part of the Loan Agreement and the equipment described thereon shall be "Equipment" as set forth in the Loan Agreement. 3. Except as specifically amended hereby, the terms and conditions of the Loan Agreement are hereby reaffirmed and remain in full force and effect, and from and after the date hereof the "Agreement" shall mean the "Agreement" as amended by this Amendment. 4. This Amendment may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. 1 IN WITNESS WHEREOF, Borrower and Lender have duly executed and delivered this Amendment as of the day and year first above written. BORROWER CYTOKINETICS, INC Signature: /s/ JAMES SABRY ---------------- Print Name: JAMES SABRY Title: CEO ACCEPTED IN ROSEMONT, ILLINOIS LENDER COMDISCO, INC. Signature: _________________________ Print Name: ________________________ Title: _____________________________ 2 EXHIBIT B CYTOKINETICS SCHEDULE OF FIXED ASSETS